Reaction

Yellow Skin reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,629 reports · 84 co-occurring drugs

As of the last recalculation, Yellow Skin appears in 4,629 FAERS reports alongside 84 co-occurring drug terms. The strongest observed disproportionality signal is SUNITINIB MALATE (PRR 91.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Sunitinib Malate	680	91.0	92.6
Octreotide Acetate	100	15.0	15.0
Sorafenib	55	12.0	12.1
Regorafenib	22	8.6	8.6
Pazopanib Hydrochloride	40	6.7	6.7
Ribociclib	45	6.5	6.5
Diroximel Fumarate	17	6.4	6.4
Captopril	13	6.1	6.1
Atazanavir	19	6.0	6.0
Nitrofurantoin (Monohydrate/Macrocrystals)	21	5.7	5.7
Deferasirox	33	5.6	5.6
Eltrombopag Olamine	28	5.5	5.5
Nitrofurantoin	20	5.5	5.5
Diphenoxylate Hydrochloride And Atropine Sulfate	16	5.3	5.3
Nilotinib	33	5.1	5.1
Ribavirin	68	4.8	4.8
Entecavir	12	4.6	4.6
Felodipine Extended-Release Tablets	11	4.4	4.4
Felodipine	11	4.4	4.4
Erythropoietin	19	4.2	4.2
Avapritinib	11	4.1	4.1
Methimazole	7	4.0	4.0
Eculizumab	48	4.0	4.0
Loperamide Hydrochloride	39	3.9	3.9
Zinc	21	3.8	3.8
Zinc Chloride	21	3.8	3.8
Indapamide	15	3.8	3.8
Loperamide Hydrochloride And Dimethicone	26	3.7	3.7
Zinc Gluconate	21	3.6	3.6
Orlistat	20	3.5	3.5
Everolimus	39	3.5	3.5
Fulvestrant	25	3.4	3.4
Ketoconazole	13	3.4	3.4
Goserelin	10	3.4	3.4
Anti-Thymocyte Globulin (Rabbit)	6	3.3	3.3
Ursodiol	16	3.3	3.3
Glecaprevir And Pibrentasvir	8	3.3	3.3
Amlodipine Besylate And Valsartan	8	3.3	3.3
Ursosiol	14	3.2	3.2
Losartan	119	3.1	3.1
Rifampicin	7	3.1	3.1
Peginterferon Beta-1A	9	3.1	3.1
Loperamide Hydrochloride Oral	7	3.1	3.1
Isoniazid	11	3.1	3.1
Prochlorperazine Maleate	6	2.9	2.9
Amlodipine	168	2.9	2.9
Lanreotide Acetate	5	2.9	2.9
Peginterferon Alfa-2A	33	2.8	2.8
Abemaciclib	12	2.7	2.7
Dimethyl Fumarate	72	2.7	2.7
Vemurafenib	7	2.6	2.6
Interferon Beta-1B	11	2.6	2.6
Vismodegib	5	2.5	2.5
Nintedanib	17	2.4	2.4
Prochlorperazine	15	2.4	2.4
Ruxolitinib	38	2.4	2.4
Ravulizumab	7	2.3	2.3
Lapatinib	8	2.3	2.3
Atomoxetine Hydrochloride	12	2.3	2.3
Imatinib Mesylate	14	2.3	2.3
Cabozantinib	21	2.0	2.0
Dabrafenib	9	1.9	1.9
Lenvatinib	14	1.9	1.9
Ledipasvir And Sofosbuvir	8	1.9	1.9
Sofosbuvir	8	1.8	1.8
Dalfampridine	28	1.8	1.8
Velpatasvir And Sofosbuvir	5	1.8	1.8
Trametinib	9	1.7	1.7
Nirmatrelvir And Ritonavir	20	1.7	1.7
Tenofovir Disoproxil Fumarate	12	1.6	1.6
Ofatumumab	12	1.6	1.6
Axitinib	7	1.6	1.6
Asenapine Maleate	3	1.6	1.6
Alpelisib	3	1.5	1.5
Rucaparib	3	1.5	1.5
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	3	1.5	1.5
Emicizumab	4	1.5	1.5
Teriflunomide	13	1.3	1.3
Trifluridine And Tipiracil	3	1.3	1.3
Alirocumab	7	1.3	1.3
Palivizumab	4	1.2	1.2
Abiraterone Acetate	10	1.1	1.1
Etonogestrel	9	0.8	0.8
Tirzepatide	21	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.